These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6538503)

  • 1. Multiple myeloma with high tumour mass. Treatment with high-dose methylprednisolone, cyclophosphamide and vindesine.
    van Dobbenburgh OA; Halie MR; Piersma H; Marrink J; Ockhuizen T; Nieweg HO
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):437-9. PubMed ID: 6538503
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 3. Vindesine in refractory multiple myeloma.
    van der Lelie H; Monasch E; Pegels HG; von dem Borne AE
    Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vindesine therapy in melphalan-resistant multiple myeloma.
    Houwen B; Ockhuizen T; Marrink J; Nieweg HO
    Eur J Cancer (1965); 1981 Feb; 17(2):227-32. PubMed ID: 7262159
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress report on vindesine treatment of melphalan-resistant multiple myeloma.
    van Dobbenburgh OA; Houwen B; Halie MR; Marrink J; Ockhuizen T; Nieweg HO
    Eur J Cancer Clin Oncol; 1983 Jun; 19(6):861-2. PubMed ID: 6683653
    [No Abstract]   [Full Text] [Related]  

  • 6. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
    Forgeson GV; Selby P; Lakhani S; Zulian G; Viner C; Maitland J; McElwain TJ
    Br J Cancer; 1988 Oct; 58(4):469-73. PubMed ID: 3207601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined chemotherapy (vindesine, lomustine, cisplatin, and cyclophosphamide) and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung.
    Le Chevalier T; Arriagada R; Baldeyrou P; Martin M; Duroux P; Jacquotte A; Sancho-Garnier H; Rouesse J
    Cancer Treat Rep; 1985 May; 69(5):469-72. PubMed ID: 4039979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
    Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
    Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
    Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
    Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of advanced bone marrow neoplasms with ifosfamide combinations.
    Norberg B; Holm J; Winqvist E; Wahlin A
    Scand J Haematol; 1984 Jan; 32(1):95-100. PubMed ID: 6582586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy of metastatic primary cardiac sarcomas.
    Vergnon JM; Vincent M; Perinetti M; Loire R; Cordier JF; Brune J
    Am Heart J; 1985 Sep; 110(3):682-4. PubMed ID: 4041125
    [No Abstract]   [Full Text] [Related]  

  • 12. Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma.
    Kashyap S; Ganguly K; Bardhan G; Majumdar G
    Leuk Lymphoma; 1999 Apr; 33(3-4):407-8. PubMed ID: 10221525
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in chemotherapy of non-small cell lung cancer.
    Sculier JP; Klastersky J
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1329-33. PubMed ID: 6209142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
    Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
    Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
    Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E
    Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive treatment of multiple myeloma and criteria for complete remission.
    Gore ME; Selby PJ; Viner C; Clark PI; Meldrum M; Millar B; Bell J; Maitland JA; Milan S; Judson IR
    Lancet; 1989 Oct; 2(8668):879-82. PubMed ID: 2571812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of patients with advanced soft tissue sarcoma with use of DVA (vindesine sulfate), adriamycin and cyclophosphamide (DAC).
    Brenner J; Magill GB; Wissel P; Sordillo PP
    Cancer; 1983 Oct; 52(7):1142-5. PubMed ID: 6349786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma spermidine concentrations as early indication of response to therapy in human myeloma.
    Van Dobbenburgh OA; Houwen B; Jurjens H; Marrink J; Halie MR; Nieweg HO
    J Clin Pathol; 1983 Jul; 36(7):804-7. PubMed ID: 6863572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gentle yet effective treatment for elderly patients with refractory or relapsing multiple myeloma.
    Manoharan A
    Am J Hematol; 2000 Sep; 65(1):81-2. PubMed ID: 10936870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
    Garewal HS; Brooks RJ; Jones SE; Miller TP
    J Clin Oncol; 1983 Dec; 1(12):772-5. PubMed ID: 6422004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.